<DOC>
	<DOCNO>NCT02940990</DOCNO>
	<brief_summary>This protocol phase II multi-center randomize control trial ( RCT ) evaluate efficacy SBRT multi-metastatic NSCLC patient pan-negative driver mutation .</brief_summary>
	<brief_title>SBRT Multi-metastatic NSCLC Patients Which Are Pan-negative Driver Mutations</brief_title>
	<detailed_description>Lung cancer lead cause cancer death . Forty percent patient diagnose metastatic lung cancer , 50 % pan-negative driver mutation . The median overall survival ( OS ) patient 11 month , maintenance therapy prolong 2 month OS . The NCCN guideline recommend 4-6 cycle chemotherapy without maintenance chemotherapy . Published data show radiotherapy modulates tumor phenotype , enhances antigen presentation tumor immunogenicity . The regression out-field lesion term `` abscopal effect '' . The combination radiotherapy immunotherapeutic agent may promote host anti-tumor immune response increase rate abscopal effect.Published data show abscopal effect appear 20 % -30 % patient metastatic malignant tumor treat combination SBRT GM-CSF . The investigator evaluate efficacy combination SBRT GM-CSF multi-metastatic NSCLC participant pan-negative driver mutation . Patients enrol randomized two group . The control group receive standard regimen NCCN recommend . The experimental group receive standard chemotherapy extra SBRT primary lesion metastatic lesion combine GM-CSF . The investigator compare progress free survival ( PFS ) two group .</detailed_description>
	<mesh_term>Paclitaxel</mesh_term>
	<mesh_term>Etoposide</mesh_term>
	<mesh_term>Vinorelbine</mesh_term>
	<mesh_term>Vinblastine</mesh_term>
	<mesh_term>Gemcitabine</mesh_term>
	<mesh_term>Carboplatin</mesh_term>
	<mesh_term>Pemetrexed</mesh_term>
	<mesh_term>Albumin-Bound Paclitaxel</mesh_term>
	<criteria>Histologically proven nonsmallcell lung cancer . Stage IV accord UICC stage system ( version 7,2009 ) .The number metastatic lesion &gt; 5 Pannegative driver mutation include EGFR ALK ROS1 cMET At least Three evaluable lesion among least two must suitable SBRT . ECOG performance status 02 . Expected lifespan ≥3 month . No brain metastasis MRI . No liver metastasis abdominal CT MRI . No malignant pleural effusion pericardial effusion chest CT and/or pathology . Stable lab value : Hematological : Absolute neutrophil count ( ANC ) ≥1.5×109/L , Platelets ≥100×109/L , Hemoglobin ≥9 g/dL Renal : Creatinine OR Measured calculate creatinine clearance ( CrCl ) ( glomerular filtration rate [ GFR ] also use place creatinine CrCl ) ≤1.5× upper limit normal ( ULN ) OR ≥60 mL/min patient creatinine level &gt; 1.5× institutional ULN Hepatic : Total bilirubin ≤1.5×ULN OR Direct bilirubin ≤ULN patient total bilirubin level &gt; 1.5×ULN , Aspartate aminotransferase ( AST ) alanine aminotransferase ( ALT ) ≤2.5×ULN OR ≤5×ULN patient liver metastasis , globulin≥20 g/L , albumin≥30 g/L . Able understand give write informed consent comply study procedure . Any unstable systemic disease , include active infection , uncontrolled high blood pressure , unstable angina , newly observe angina pectoris within past 3 month , congestive heart failure ( New York heart association ( NYHA ) class II high ) , myocardial infarction onset six month include group , severe arrhythmia , liver , kidney , metabolic disease need drug therapy . Previously diagnose immunodeficiency disease . Human immunodeficiency virus ( HIV ) infection . Women pregnancy lactation . Patients mental illness , consider `` ca n't fully understand issue research '' . Cancer history . Histologically confirm small cell carcinoma non NSCLC composition cancer tissue . Brain metastasis liver metastasis malignant pleural effusion pericardial effusion . Allergy rhGMCSF accessory . Contraindications GMCSF treatment .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>November 2016</verification_date>
</DOC>